Status:

COMPLETED

A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain

Lead Sponsor:

Alza Corporation, DE, USA

Conditions:

Analgesics, Opioid

Pain

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this repeated dose study is to develop recommended dosing information for initiation of therapy with OROS Hydromorphone HCI (slow release) in patients with chronic cancer pain convertin...

Detailed Description

This randomized (patients assigned to treatment by chance), single-blind (with respect to dose), open-label (patients know what study treatment, not dose, they are receiving) repeated dose study evalu...

Eligibility Criteria

Inclusion

  • Patients who have chronic cancer pain who are currently receiving strong oral or transdermal opioid analgesics or patients suitable for advancement of therapy to step 3 on the WHO (World Health Organization) analgesic ladder
  • patients who can reasonably be expected to have stable opioid requirements for the duration of the study

Exclusion

  • Patients intolerant of or hypersensitive to hydromorphone (or other opioid agonists)
  • patients who are pregnant or breast-feeding
  • patients with severe respiratory compromise or severely depressed ventilatory function
  • patients with any gastrointestinal disorder or acute abdominal conditions including pre-existing severe GI narrowing (pathologic or iatrogenic), that may affect the absorption or transit of orally administered drugs
  • patients with clinically significant impaired renal or hepatic function, Addison's disease, hypothyroidism, prostatic hypertrophy, or urethral stricture, dysphagia or are unable to swallow tablets or any significant CNS disorder, including but not limited to head injury, intracranial lesion, increased intracranial pressure, seizure disorder, stroke within the past 6 months, and disorders of cognition

Key Trial Info

Start Date :

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 1999

Estimated Enrollment :

463 Patients enrolled

Trial Details

Trial ID

NCT00411034

End Date

September 1 1999

Last Update

April 27 2010

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain | DecenTrialz